Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity

BMC Gastroenterology

Volumn 13, Issue 1, 2013, Pages

  Buryova, Halka ^a   Chalupsky, Karel ^a   Zbodakova, Olga ^a   Kanchev, Ivan ^a   Jirouskova, Marketa ^a   Gregor, Martin ^a   Sedlacek, Radislav ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

ADAM17; Cholestasis; Liver; Shedding; Ursodeoxycholic acid

Indexed keywords

ADAM PROTEIN; ADAM17 PROTEIN; ALKALINE PHOSPHATASE; GELATINASE; GLYCOGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHORBOL 13 ACETATE 12 MYRISTATE; SCATTER FACTOR RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; CELL STRAIN HEPG2; CHOLESTASIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCOGEN LIVER LEVEL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIVER CELL; LIVER HISTOLOGY; LIVER PROTECTION; LIVER WEIGHT; MALE; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION;

ADAM PROTEINS; ANIMALS; BILE DUCTS; CHOLAGOGUES AND CHOLERETICS; CHOLESTASIS; HEP G2 CELLS; HEPATOCYTES; HUMANS; LIGATION; LIVER; MAP KINASE SIGNALING SYSTEM; MICE; PROTO-ONCOGENE PROTEINS C-MET; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR-ALPHA; URSODEOXYCHOLIC ACID;

EID: 84886522539     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-13-155     Document Type: Article

References (50)

1. Poupon RE. Ursodeoxycholic acid for primary biliary cirrhosis: lessons from the past-issues for the future. J Hepatol 2000, 32(4):685-688. 10.1016/S0168-8278(00)80232-9, 10782919.
2. Okada K, Shoda J, Taguchi K, Maher JM, Ishizaki K, Inoue Y, Ohtsuki M, Goto N, Takeda K, Utsunomiya H, et al. Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxification, and antioxidative stress systems in mice. Am J Physiol Gastrointest Liver Physiol 2008, 295(4):G735-747. 10.1152/ajpgi.90321.2008, 18687751.
3. Uriz M, Saez E, Prieto J, Medina JF, Banales JM. Ursodeoxycholic acid is conjugated with taurine to promote secretin-stimulated biliary hydrocholeresis in the normal rat. PloS one 2011, 6(12):e28717. 10.1371/journal.pone.0028717, 3237485, 22194894.
4. Maillette De Buy Wenniger L, Beuers U. Bile salts and cholestasis. Dig Liver Dis 2010, 42(6):409-418. 10.1016/j.dld.2010.03.015, 20434968.
5. Yerushalmi B, Dahl R, Devereaux MW, Gumpricht E, Sokol RJ. Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition. Hepatology 2001, 33(3):616-626. 10.1053/jhep.2001.22702, 11230742.
6. Xie Q, Khaoustov VI, Chung CC, Sohn J, Krishnan B, Lewis DE, Yoffe B. Effect of tauroursodeoxycholic acid on endoplasmic reticulum stress-induced caspase-12 activation. Hepatology 2002, 36(3):592-601. 10.1053/jhep.2002.35441, 12198651.
7. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, Gorgun CZ, Hotamisligil GS. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006, 313(5790):1137-1140. 10.1126/science.1128294, 16931765.
8. Lapenna D, Ciofani G, Festi D, Neri M, Pierdomenico SD, Giamberardino MA, Cuccurullo F. Antioxidant properties of ursodeoxycholic acid. Biochem Pharmacol 2002, 64(11):1661-1667. 10.1016/S0006-2952(02)01391-6, 12429355.
9. Mitsuyoshi H, Nakashima T, Sumida Y, Yoh T, Nakajima Y, Ishikawa H, Inaba K, Sakamoto Y, Okanoue T, Kashima K. Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants. Biochem Biophys Res Commun 1999, 263(2):537-542. 10.1006/bbrc.1999.1403, 10491327.
10. Zhou Y, Doyen R, Lichtenberger LM. The role of membrane cholesterol in determining bile acid cytotoxicity and cytoprotection of ursodeoxycholic acid. Biochim Biophys Acta 2009, 1788(2):507-513. 10.1016/j.bbamem.2008.12.008, 3805258, 19150330.
11. Amaral JD, Castro RE, Sola S, Steer CJ, Rodrigues CM. Ursodeoxycholic acid modulates the ubiquitin-proteasome degradation pathway of p53. Biochem Biophys Res Commun 2010, 400(4):649-654. 10.1016/j.bbrc.2010.08.121, 20807506.
12. Heuman DM, Pandak WM, Hylemon PB, Vlahcevic ZR. Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: in vitro studies in rat hepatocytes and human erythrocytes. Hepatology 1991, 14(5):920-926. 10.1002/hep.1840140527, 1937396.
13. Hillaire S, Boucher E, Calmus Y, Gane P, Ballet F, Franco D, Moukthar M, Poupon R. Effects of bile acids and cholestasis on major histocompatibility complex class I in human and rat hepatocytes. Gastroenterol 1994, 107(3):781-788.
14. Theret N, Musso O, Turlin B, Lotrian D, Bioulac-Sage P, Campion JP, Boudjema K, Clement B. Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology 2001, 34(1):82-88. 10.1053/jhep.2001.25758, 11431737.
15. Scheller J, Chalaris A, Garbers C, Rose-John S. ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol 2011, 32(8):380-387. 10.1016/j.it.2011.05.005, 21752713.
16. Doggrell SA. TACE inhibition: a new approach to treating inflammation. Expert Opin Investig Drugs 2002, 11(7):1003-1006. 10.1517/13543784.11.7.1003, 12084010.
17. Moss ML, Sklair-Tavron L, Nudelman R. Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol 2008, 4(6):300-309.
18. de Meijer VE, Sverdlov DY, Popov Y, Le HD, Meisel JA, Nose V, Schuppan D, Puder M. Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice. PloS one 2010, 5(6):e11256. 10.1371/journal.pone.0011256, 2892485, 20593020.
19. Amour A, Slocombe PM, Webster A, Butler M, Knight CG, Smith BJ, Stephens PE, Shelley C, Hutton M, Knauper V, et al. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 1998, 435(1):39-44. 10.1016/S0014-5793(98)01031-X, 9755855.
20. Mohammed FF, Smookler DS, Taylor SE, Fingleton B, Kassiri Z, Sanchez OH, English JL, Matrisian LM, Au B, Yeh WC, et al. Abnormal TNF activity in Timp3-/- mice leads to chronic hepatic inflammation and failure of liver regeneration. Nat Genet 2004, 36(9):969-977. 10.1038/ng1413, 15322543.
21. Neuman M, Angulo P, Malkiewicz I, Jorgensen R, Shear N, Dickson ER, Haber J, Katz G, Lindor K. Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. J Gastroenterol Hepatol 2002, 17(2):196-202. 10.1046/j.1440-1746.2002.02672.x, 11966951.
22. Ishizaki K, Iwaki T, Kinoshita S, Koyama M, Fukunari A, Tanaka H, Tsurufuji M, Sakata K, Maeda Y, Imada T, et al. Ursodeoxycholic acid protects concanavalin A-induced mouse liver injury through inhibition of intrahepatic tumor necrosis factor-alpha and macrophage inflammatory protein-2 production. Eur J Pharmacol 2008, 578(1):57-64. 10.1016/j.ejphar.2007.08.031, 17888421.
23. Osmanagic-Myers S, Gregor M, Walko G, Burgstaller G, Reipert S, Wiche G. Plectin-controlled keratin cytoarchitecture affects MAP kinases involved in cellular stress response and migration. J Cell Biol 2006, 174(4):557-568. 10.1083/jcb.200605172, 2064261, 16908671.
24. Chalupsky K, Kanchev I, Zbodakova O, Buryova H, Jirouskova M, Korinek V, Gregor M, Sedlacek R. ADAM10/17-Dependent Release of Soluble c-Met Correlates with Hepatocellular Damage. Folia Biol 2013, 59(2):76-86.
25. Sadowski T, Dietrich S, Koschinsky F, Sedlacek R. Matrix metalloproteinase 19 regulates insulin-like growth factor-mediated proliferation, migration, and adhesion in human keratinocytes through proteolysis of insulin-like growth factor binding protein-3. Mol Biol Cell 2003, 14(11):4569-4580. 10.1091/mbc.E03-01-0009, 266773, 12937269.
26. Constandinou C, Henderson N, Iredale JP. Modeling liver fibrosis in rodents. Methods Mol Med 2005, 117:237-250.
27. Kveiborg M, Instrell R, Rowlands C, Howell M, Parker PJ. PKCalpha and PKCdelta regulate ADAM17-mediated ectodomain shedding of heparin binding-EGF through separate pathways. PloS one 2011, 6(2):e17168. 10.1371/journal.pone.0017168, 3046143, 21386996.
28. Inagaki T, Moschetta A, Lee YK, Peng L, Zhao G, Downes M, Yu RT, Shelton JM, Richardson JA, Repa JJ, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A 2006, 103(10):3920-3925. 10.1073/pnas.0509592103, 1450165, 16473946.
29. Moss ML, Rasmussen FH. Fluorescent substrates for the proteinases ADAM17, ADAM10, ADAM8, and ADAM12 useful for high-throughput inhibitor screening. Anal Biochem 2007, 366(2):144-148. 10.1016/j.ab.2007.04.043, 17548045.
30. Massague J, Pandiella A. Membrane-anchored growth factors. Annu Rev Biochem 1993, 62:515-541. 10.1146/annurev.bi.62.070193.002503, 8394682.
31. Park S, Jung HH, Park YH, Ahn JS, Im YH. ERK/MAPK pathways play critical roles in EGFR ligands-induced MMP1 expression. Biochem Biophys Res Commun 2011, 407(4):680-686. 10.1016/j.bbrc.2011.03.075, 21440529.
32. Zheng Y, Saftig P, Hartmann D, Blobel C. Evaluation of the contribution of different ADAMs to tumor necrosis factor alpha (TNFalpha) shedding and of the function of the TNFalpha ectodomain in ensuring selective stimulated shedding by the TNFalpha convertase (TACE/ADAM17). J Biol Chem 2004, 279(41):42898-42906. 10.1074/jbc.M403193200, 15292243.
33. Knittel T, Mehde M, Grundmann A, Saile B, Scharf JG, Ramadori G. Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat. Histochem Cell Biol 2000, 113(6):443-453.
34. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 2007, 117(3):524-529. 10.1172/JCI31487, 1804380, 17332879.
35. Jirouskova M, Zbodakova O, Gregor M, Chalupsky K, Sarnova L, Hajduch M, Ehrmann J, Jirkovska M, Sedlacek R. Hepatoprotective Effect of MMP-19 Deficiency in a Mouse Model of Chronic Liver Fibrosis. PloS one 2012, 7(10):e46271. 10.1371/journal.pone.0046271, 3467204, 23056273.
36. Roderfeld M, Graf J, Giese B, Salguero-Palacios R, Tschuschner A, Muller-Newen G, Roeb E. Latent MMP-9 is bound to TIMP-1 before secretion. Biol Chem 2007, 388(11):1227-1234.
37. Alpini G, Baiocchi L, Glaser S, Ueno Y, Marzioni M, Francis H, Phinizy JL, Angelico M, Lesage G. Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha. Hepatology 2002, 35(5):1041-1052. 10.1053/jhep.2002.32712, 11981754.
38. He H, Mennone A, Boyer JL, Cai SY. Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells. Hepatology 2011, 53(2):548-557. 10.1002/hep.24047, 3069505, 21274875.
39. Combes B, Carithers RL, Maddrey WC, Munoz S, Garcia-Tsao G, Bonner GF, Boyer JL, Luketic VA, Shiffman ML, Peters MG, et al. Biliary bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1999, 29(6):1649-1654. 10.1002/hep.510290618, 10347103.
40. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005, 353(12):1261-1273. 10.1056/NEJMra043898, 16177252.
41. Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009, 50(3):808-814. 10.1002/hep.23082, 2758780, 19585548.
42. Murthy A, Defamie V, Smookler DS, Di Grappa MA, Horiuchi K, Federici M, Sibilia M, Blobel CP, Khokha R. Ectodomain shedding of EGFR ligands and TNFR1 dictates hepatocyte apoptosis during fulminant hepatitis in mice. J Clin Invest 2010, 120(8):2731-2744. 10.1172/JCI42686, 2913323, 20628198.
43. Weber S, Saftig P. Ectodomain shedding and ADAMs in development. Development 2012, 139(20):3693-3709. 10.1242/dev.076398, 22991436.
44. Fitzgerald ML, Wang Z, Park PW, Murphy G, Bernfield M. Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol 2000, 148(4):811-824. 10.1083/jcb.148.4.811, 2169376, 10684261.
45. Doedens JR, Mahimkar RM, Black RA. TACE/ADAM-17 enzymatic activity is increased in response to cellular stimulation. Biochem Biophys Res Commun 2003, 308(2):331-338. 10.1016/S0006-291X(03)01381-0, 12901873.
46. Kopitz C, Gerg M, Bandapalli OR, Ister D, Pennington CJ, Hauser S, Flechsig C, Krell HW, Antolovic D, Brew K, et al. Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res 2007, 67(18):8615-8623. 10.1158/0008-5472.CAN-07-0232, 17875701.
47. Yang Y, Wang Y, Zeng X, Ma XJ, Zhao Y, Qiao J, Cao B, Li YX, Ji L, Wang YL. Self-Control of HGF Regulation on Human Trophoblast Cell Invasion via Enhancing c-Met Receptor Shedding by ADAM10 and ADAM17. J Clin Endocrinol Metab 2012, 97(8):E1390-1401. 10.1210/jc.2012-1150, 22689693.
48. Son G, Hirano T, Seki E, Iimuro Y, Nukiwa T, Matsumoto K, Nakamura T, Fujimoto J. Blockage of HGF/c-Met system by gene therapy (adenovirus-mediated NK4 gene) suppresses hepatocellular carcinoma in mice. J Hepatol 2006, 45(5):688-695. 10.1016/j.jhep.2006.04.011, 16839638.
49. Michalopoulos GK. Liver regeneration after partial hepatectomy: critical analysis of mechanistic dilemmas. Am J Pathol 2010, 176(1):2-13. 10.2353/ajpath.2010.090675, 2797862, 20019184.
50. Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999, 354(9184):1053-1060. 10.1016/S0140-6736(98)11293-X, 10509495.